Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China.
Although Metavir and Fibrosis-4 (FIB-4) scores are typically used to assess the severity of liver fibrosis, the relationship between these scores and patient outcome in hepatocellular carcinoma (HCC) is unclear. The aim of this study was to evaluate the prognostic value of the severity of hepatic fibrosis in HBV-related HCC patients after curative resection. We examined the prognostic roles of the Metavir and preoperative FIB-4 scores in 432 HBV-HCC patients who underwent curative resection at two different medical centers located in western (Chongqing) and eastern (Shanghai) China. In the testing set (n = 108), the Metavir, FIB-4, and combined Metavir/FIB-4 scores were predictive of overall survival (OS) and recurrence-free survival (RFS). Additionally, they were associated with several clinicopathologic variables. In the validation set (n = 324), the Metavir, FIB-4, and combined Metavir/FIB-4 scores were associated with poor prognosis in HCC patients after curative resection. Importantly, in the negative alpha-fetoprotein subgroup (≤ 20 ng/mL), the FIB-4 index (I vs. II) could discriminate between patient outcomes (high or low OS and RFS). Thus Metavir, preoperative FIB-4, and combined Metavir/FIB-4 scores are prognostic markers in HBV-HCC patients after curative hepatectomy.
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rui
R
Liao
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi-Peng
YP
Fu
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ting
T
Wang
Department of General Surgery, Mianyang Central Hospital, Mianyang, China.
Zhi-Gang
ZG
Deng
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
De-Wei
DW
Li
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.|Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Jia
J
Fan
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.|Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Jian
J
Zhou
Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, California, USA.
Gen-Sheng
GS
Feng
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Shuang-Jian
SJ
Qiu
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Cheng-You
CY
Du
D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000601:surgery / Q000821:virology; D002681:China; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D006515:Hepatitis B virus / Q000472:pathogenicity*; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology* / Q000601:surgery / Q000821:virology; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery / Q000821:virology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
D014408:Biomarkers, Tumor; D000509:alpha-Fetoproteins
cancer; hepatitis B virus; liver cirrhosis; prognosis; surgery
Gut. 2014 May;63(5):844-55
24531850
Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):691-2
23147657
Hepatology. 2002 Oct;36(4 Pt 1):986-92
12297848
CA Cancer J Clin. 2012 Nov-Dec;62(6):394-9
23070690
Science. 2007 Jul 6;317(5834):121-4
17615358
J Viral Hepat. 2014 Dec;21(12):930-7
24472062
Cell. 2009 Dec 24;139(7):1315-26
20064377
Gastroenterology. 2013 Mar;144(3):512-27
23313965
N Engl J Med. 2008 Nov 6;359(19):1995-2004
18923165
J Clin Oncol. 2010 Apr 1;28(10):1660-5
20194845
Hepatology. 2011 Mar;53(3):885-94
21319193
J Clin Oncol. 2008 Dec 1;26(34):5576-82
18955457
Am J Gastroenterol. 2006 Mar;101(3):524-32
16542289
J Clin Oncol. 2008 Jan 10;26(2):177-82
18182659
J Viral Hepat. 1997 May;4(3):199-208
9181529
Hepat Mon. 2013 May 08;13(5):e8352
23967022
J Hepatol. 2014 Apr;60(4):706-14
24291240
J Hepatol. 2003 Feb;38(2):223-9
12547412
Hepatology. 2006 Jun;43(6):1317-25
16729309
Oncotarget. 2016 May 24;7(21):30951-61
27129159
Nat Rev Cancer. 2006 Sep;6(9):674-87
16929323
Hepatology. 2003 Aug;38(2):518-26
12883497
J Hepatol. 2014 Jul;61(1):22-7
24607623
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2512-7
22028407
Br J Cancer. 2013 Aug 6;109(3):573-81
23846171
Surgery. 2015 Apr;157(4):699-707
25704421
CA Cancer J Clin. 2013 Jan;63(1):11-30
23335087
Am J Gastroenterol. 1998 Jan;93(1):44-8
9448172
J Am Coll Surg. 2006 Feb;202(2):275-83
16427553
Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1076-81
23510962
Hepatology. 1996 Aug;24(2):289-93
8690394
Ann Surg Oncol. 2012 Dec;19(13):4278-86
22752370
Cell. 2013 Apr 11;153(2):449-60
23562644
Eur J Cancer. 2007 Apr;43(6):979-92
17291746
Cancer Lett. 2014 Feb 28;343(2):161-71
24120759
Ann Surg Oncol. 2009 Jul;16(7):1832-42
19365625
Cancer Cell. 2006 Aug;10(2):99-111
16904609
J Hepatol. 2014 Feb;60(2):339-45
24128413
Am J Gastroenterol. 2001 Nov;96(11):3142-6
11721762